Nachega Jean B, Uthman Olalekan A, Mofenson Lynne M, Anderson Jean R, Kanters Steve, Renaud Francoise, Ford Nathan, Essajee Shaffiq, Doherty Meg C, Mills Edward J
*Departments of Epidemiology, Microbiology and Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; †Department of Medicine, Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa; ‡Departments of Epidemiology and International Health, Johns Hopkins University, Baltimore, MD; §Centre for Applied Health Research & Delivery, Warwick Medical School, The University of Warwick, Coventry, United Kingdom; ‖Department of Public Health (IHCAR), Karolinska Institute, Stockholm, Sweden; ¶Department of Global Health, Centre for Evidence-Based Health Care, Stellenbosch University, Tygerberg, South Africa; #Elizabeth Glazer Pediatric AIDS Foundation, Washington, DC; **Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD; ††Department of Statistics, University of British Columbia, Vancouver, Canada; ‡‡Global Evaluative Science, Vancouver, Canada; and §§Department of HIV, World Health Organization, Geneva, Switzerland.
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):1-12. doi: 10.1097/QAI.0000000000001359.
There are limited data on adverse effects of tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART) on pregnant women and their infants.
We conducted a systematic review of studies published between January 1980 and January 2017 that compared adverse outcomes in HIV-infected women receiving TDF- vs. non-TDF-based ART during pregnancy. The risk ratio (RR) for associations was pooled using a fixed-effects model.
Seventeen studies met the study inclusion criteria. We found that the rate of preterm (<37 weeks gestation) delivery (RR = 0.90, 95% confidence interval [CI]: 0.81 to 0.99, I = 59%) and stillbirth (RR = 0.60, 95% CI: 0.43 to 0.84, I = 72.0%) were significantly lower in women exposed (vs. not) to TDF-based ART regimen. We found no increased risk in maternal severe (grade 3) or potentially life-threatening (grade 4) adverse events (RR = 0.62; 95% CI: 0.30 to 1.29), miscarriage (RR = 1.09; 95% CI: 0.80 to 1.48), very preterm (<34 weeks gestation) delivery (RR = 1.08, 95% CI: 0.72 to 1.62), small for gestational age (RR = 0.87, 95% CI: 0.67 to 1.13), low birth weight (RR = 0.91; 95% CI: 0.80 to 1.04), very low birth weight (RR = 3.18; 95% CI: 0.65 to 15.63), congenital anomalies (RR = 1.03; 95% CI: 0.83 to 1.28), infant adverse outcomes or infant mortality (age >14 days) (RR = 0.65; 95% CI: 0.23 to 1.85), but increased neonatal mortality (age <14 days) risk (RR = 5.64, 95% CI: 1.70 to 18.79) with TDR-based ART exposure. No differences were found for anthropomorphic parameters at birth; one study reported minor differences in z-scores for length and head circumference at age 1 year.
TDF-based ART in pregnancy seems generally safe for women and their infants. However, data remain limited and further studies are needed, particularly to assess neonatal mortality and infant growth/bone effects.
关于基于替诺福韦酯(TDF)的抗逆转录病毒疗法(ART)对孕妇及其婴儿的不良反应的数据有限。
我们对1980年1月至2017年1月发表的研究进行了系统评价,这些研究比较了孕期接受基于TDF的ART与非基于TDF的ART的HIV感染女性的不良结局。使用固定效应模型汇总关联的风险比(RR)。
17项研究符合纳入标准。我们发现,暴露于基于TDF的ART方案的女性,其早产(妊娠<37周)率(RR = 0.90,95%置信区间[CI]:0.81至0.99,I² = 59%)和死产率(RR = 0.60,95%CI:0.43至0.84,I² = 72.0%)显著低于未暴露者。我们发现,母亲严重(3级)或潜在危及生命(4级)不良事件(RR = 0.62;95%CI:0.30至1.29)、流产(RR = 1.09;95%CI:0.80至1.48)、极早产(妊娠<34周)率(RR = 1.08,95%CI:0.72至1.62)、小于胎龄儿(RR = 0.87,95%CI:0.67至1.13)、低出生体重(RR = 0.91;95%CI:0.80至1.04)、极低出生体重(RR = 3.18;95%CI:0.65至15.63)、先天性异常(RR = 1.03;95%CI:0.83至1.28)、婴儿不良结局或婴儿死亡率(年龄>14天)(RR = 0.65;95%CI:0.23至1.85)的风险没有增加,但基于TDR的ART暴露会增加新生儿死亡率(年龄<14天)风险(RR = 5.64,95%CI:1.70至18.79)。出生时人体测量参数未发现差异;一项研究报告了1岁时身长和头围的z评分有微小差异。
孕期基于TDF的ART对女性及其婴儿似乎总体安全。然而,数据仍然有限,需要进一步研究,特别是评估新生儿死亡率和婴儿生长/骨骼影响。